查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401882

2030 年卵巢癌市場預測：按類型、治療、診斷測試、最終用戶和地區進行的全球分析

Ovarian Cancer Market Forecasts to 2030 - Global Analysis By Type (Germ Cell Tumors, Epithelial Tumors, Primary Peritoneal Cancer and Stromal Tumors), Therapeutic Treatment, Diagnostic Test, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球卵巢癌市場規模為 31.8 億美元，預計預測期內複合年成長率為 26.0%，到 2030 年將達到 160.1 億美元。

一種始於卵巢（女性生殖器官）的癌症稱為卵巢癌。卵巢是產生卵子和雌性荷爾蒙的地方，這種在女性中排名第七的疾病可能要等到進展到腹部或骨盆時才能被診斷出來。診斷包括影像檢查（超音波、 電腦斷層掃描、MRI）、血液檢查（CA-125腫瘤標記）、骨盆檢查，有時還需要切片檢查以確認癌細胞的存在。

根據 2022 年 1 月美國癌症協會 (ACS) 的報告，卵巢癌是美國第九大常見癌症，也是女性癌症死亡的第五大原因。

卵巢癌盛行率增加

已開發國家和新興國家的經濟都在擴張，刺激了醫療保健的普及。因此，它有助於世界市場的發展。卵巢癌的盛行率預計將上升，人口中老年女性的數量、新治療方法和治療方法的易用性以及醫療保健成本的上升預計將促進全球市場的成長。隨著女性人口高齡化，卵巢癌的發生率不斷增加。卵巢癌發病率上升、新藥和治療方法的推出、醫療保健成本上升以及政府融資增加正在推動該行業的發展。

缺乏特異性的篩檢測試

由於卵巢癌通常在疾病階段的晚期才被發現，因此治療選擇有限且治療結果通常較差。快速檢測和介入的主要障礙之一是缺乏有效的早期篩檢技術。此外，即使治療方法取得了突破性進展，某些卵巢癌亞型也可能對化療和標靶治療等傳統藥物產生抗藥性。由於缺乏可行的治療方法，抗藥性和復發性卵巢卵巢的成功治療受到威脅，從而阻礙了市場成長。

醫療保健意識不斷增強

提高意識將幫助女性識別卵巢癌的徵兆和危險因子。提高認知可以鼓勵人們更快就醫，從而更快地進行診斷和干涉，並有助於在更容易控制的階段更早發現疾病。意識的提高有助於患者和醫療保健專業人員之間更好的溝通。患者向醫生諮詢自己的症狀和危險因素變得越來越普遍，這有助於及時評估和適當的診斷治療。

卵巢癌的複雜性與異質性

卵巢癌的多種亞型和分子特徵導致治療困難。對一種亞型有效的治療可能對另一種亞型較不有效。根據個別患者獨特的基因譜和亞型治療方法很困難，需要個體化的方法。卵巢癌的複雜性使得制定一致的治療計畫變得困難。此外，當治療技術不一致時，很難提供明確的建議，這會導致治療不一致，並且很難為每位患者確定最佳的治療方案。

COVID-19 的影響

在大流行期間，許多標準篩檢和診斷程序，包括卵巢癌的篩檢和診斷程序被取消或推遲，從而減少了癌症的早期發現，導致醫療保健設施的使用機會減少，並因COVID-19 而減少了護理。診斷可能因到優先順序。疫情影響了一些研究卵巢癌新療法的臨床試驗，導致臨床試驗入組人數減少，一些已經在進行的試驗為了確保參與者的安全和預防疫情，已經實施變更或暫停，以符合相關規定。

生殖細胞腫瘤預計將成為預測期內最大的部分

生殖細胞腫瘤領域有望迎來良好的發展，因為它比其他類型的卵巢癌（例如上皮性卵巢癌）更罕見，在年輕女性中更常見，並且通常具有良好的預後。由於生殖細胞腫瘤經常影響年輕女性，因此我們努力在治療期間盡可能保持生育能力。有效治癒惡性同時保留生殖功能的手術技術經常在這一人群中進行研究，這正在擴大市場。

荷爾蒙治療領域預計在預測期內複合年成長率最高

對於某些卵巢癌，特別是低惡性漿液性卵巢癌，荷爾蒙治療可能是一種選擇，且荷爾蒙治療領域預計在預測期內將以最高複合年成長率成長。根據一項研究，一小部分 LGSC 患者可能會從荷爾蒙治療中獲益，例如Aromatase抑制劑和荷爾蒙受體拮抗，以減緩腫瘤生長。此外，當傳統治療方法經過試驗後，不再能有效控制症狀或減緩疾病進展時，荷爾蒙治療被視為復發性或抗藥性卵巢卵巢的安寧療護選擇。

佔有率最大的地區

由於該地區製藥公司的存在以及中國和印度等人口大國的購買力不斷上升，預計亞太地區將在預測期內佔據最大的市場佔有率。此外，個體化醫療支出的增加和高科技流程的使用、龐大的人口基數和未滿足的醫療需求都促進了卵巢藥物的市場開拓，而該地區可支配收入的增加也促進了市場的成長。

複合年成長率最高的地區：

北美地區在預測期內佔據最大的收益佔有率，主導市場，因為先進的醫療設施和發達的醫療基礎設施使該地區能夠早期診斷和治療卵巢癌，預計複合年成長率將在北美最高。此外，患者知識的提高也提高了篩檢和檢出率。此外，北美擁有許多致力於開發新型癌症治療方法的學術中心、研究機構和製藥公司。根據美國癌症協會的報告，卵巢癌是女性癌症相關死亡的第六大原因，推動了該地區的市場成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球卵巢癌市場：依類型

  • 生殖細胞腫瘤
  • 上皮性腫瘤
  • 原發性腹膜癌
  • 間質瘤

第6章全球卵巢癌市場：依治療分類

  • 放射治療
  • 化療
  • 荷爾蒙治療
  • 標靶治療
    • PARP抑制劑
    • 血管新生抑制劑
    • PD-L1抑制劑
    • 其他標靶治療
  • 外科手術
  • 其他治療

第7章全球卵巢癌市場：透過診斷測試

  • 超音波
  • 電腦斷層掃描 (CT) 掃描
  • 灌腸鋇劑X光檢查
  • 胸部X光檢查
  • 正子斷層掃描 (PET) 掃描
  • 磁振造影(MRI) 掃描
  • 其他診斷測試

第8章全球卵巢癌市場：依最終用戶分類

  • 診斷中心
  • 醫院
  • 線上藥房
  • 藥局
  • 其他最終用戶

第9章全球卵巢癌市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Abbvie Inc
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc
  • Merck KGaA
  • Novogen, Inc.
  • Oasmia Pharmaceutical Inc.
  • Pfizer, Inc.
  • Siemens Healthineers AG
  • Tesaro Inc.
  • Vivesto AB
Product Code: SMRC24402

According to Stratistics MRC, the Global Ovarian Cancer Market is accounted for $3.18 billion in 2023 and is expected to reach $16.01 billion by 2030 growing at a CAGR of 26.0% during the forecast period. One kind of cancer that starts in the female reproductive system, the ovaries is called ovarian cancer. The ovaries are where eggs and female hormones are produced and this disease, which ranks seventh in the globe among women, sometimes stays undiagnosed until it has progressed to the abdomen and pelvic. A combination of imaging tests (ultrasound, CT scan, MRI), blood tests (CA-125 tumor marker), pelvic examinations, and occasionally a biopsy to confirm the presence of cancer cells are used in the diagnosis process.

According to the American Cancer Society (ACS) report in January 2022, ovarian cancer was the ninth most common cancer and the fifth leading cause of cancer death among women in the United States.

Market Dynamics:

Driver:

Increased prevalence of ovarian cancer

Both developed and developing countries' expanding economies are fuelling the spread of healthcare. They are therefore contributing to the advancement of the worldwide market. Ovarian cancer incidence is predicted to raise, the number of older women in the population, the ease of using new treatments and therapies, and growing healthcare costs are all likely to contribute to the growth of the worldwide market. Ovarian cancer has increased in frequency as the female population has aged. The industry is driven by rising rates of ovarian cancer, new drug and treatment introductions, rising healthcare costs, and rising government financing.

Restraint:

Lack of specific screening tests

Due to the fact that ovarian cancer is frequently discovered later in the disease's progression, treatment choices are limited and results are generally worse. One major obstacle that prevents prompt identification and intervention is the absence of effective early screening techniques. Moreover, certain subtypes of ovarian cancer may remain resistant to traditional medicines such as chemotherapy or targeted treatments, even with breakthroughs in treatment. Successful care of resistant or recurrent ovarian cancer is threatened by the scarcity of viable medications thus impeding the growth of the market.

Opportunity:

Rising healthcare awareness

Women are more likely to identify the signs and risk factors of ovarian cancer when there is greater awareness. Increased awareness encourages people to seek medical care sooner, which results in rapid diagnosis and intervention and may help identify the illness at an earlier, more manageable stage. Better communication between patients and healthcare professionals is fostered by increased awareness. It is increasingly common for patients to talk to their doctors about symptoms or risk factors that they find troubling, which makes it easier for prompt assessments and relevant diagnostic procedures.

Threat:

Complexity and heterogeneity of ovarian cancer

Treatment difficulties are a result of the many subtypes and molecular traits of ovarian cancer. Treatments that work for one subtype might not work as well for another. Treatment regimen customization for individual patients based on their unique genetic profile and subtype can be challenging and call for individualized methods. The complexity of ovarian cancer makes it difficult to establish consistent treatment plans. Moreover, it is challenging to provide clear recommendations when treatment techniques are inconsistent, which might result in care that is inconsistent and make it challenging to identify the best course of action for each patient.

COVID-19 Impact

Numerous standard checkups and diagnostic procedures including those for ovarian cancer were cancelled or postponed during the outbreak and decreased early cancer detection may have resulted in later diagnoses due to reduced access to healthcare facilities and prioritizing of COVID-19 care. The pandemic had an impact on several clinical studies looking at new ovarian cancer therapy thus trial enrollment declined, and several that were already underway had their modifications or temporary pauses implemented to guarantee participant safety and adherence to pandemic-related regulations.

The germ cell tumors segment is expected to be the largest during the forecast period

The germ cell tumors segment is estimated to have a lucrative growth, as these are more frequent in younger women and often have a better prognosis, although being less common than other kinds of ovarian cancer (such as epithelial ovarian cancer). Since younger women are frequently affected by germ cell tumors, efforts are made to maintain fertility if possible while undergoing therapy. In this population, surgical methods that efficiently cure the malignancy while preserving reproductive function are frequently investigated which enhances the market.

The hormone therapy segment is expected to have the highest CAGR during the forecast period

The hormone therapy segment is anticipated to witness the highest CAGR growth during the forecast period, because for some ovarian cancers, especially low-grade serous ovarian carcinoma, hormone treatment may be an option. According to certain studies, a small proportion of individuals with LGSC may benefit somewhat from hormone therapies like aromatase inhibitors or hormonal receptor blockers to slow the growth of their tumors. Additionally, hormone therapy may be investigated as a palliative option in cases of ovarian cancer that is recurring or resistant, where traditional therapies have been tried and tested and are no longer working to control symptoms or reduce the disease's development.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India. Furthermore, the market is growing due to an increase in spending on customized medicine and the use of high-tech processes to enhance the development of medications for ovarian cancer and a large population base, the existence of unmet medical demands, and an increase in the region's disposable income all contribute to the market's growth.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, as North America held the greatest revenue share of dominating the market and ovarian cancer can be diagnosed and treated earlier in the region because to its sophisticated medical facilities and well-developed healthcare infrastructure. Patients' growing knowledge has resulted in higher screening and detection rates. Furthermore, there are a large number of academic centers, research facilities, and pharmaceutical businesses in North America that are dedicated to creating novel cancer treatments. The American Cancer Society reports that the sixth most common cause of cancer-related deaths in women is ovarian cancer which drives the growth of the market in this region.

Key players in the market:

Some of the key players profiled in the Ovarian Cancer Market include Abbvie Inc, Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Merck KGaA, Novogen, Inc., Oasmia Pharmaceutical Inc., Pfizer, Inc., Siemens Healthineers AG, Tesaro Inc. and Vivesto AB

Key Developments:

In November 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from two new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of XARELTO® (rivaroxaban [2.5 mg twice daily plus aspirin 100 mg once daily]) over standard of care (aspirin alone).

In October 2023, GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK. The company's new UK STEM equity programme aims to help reduce the significant barriers to entry faced by women and young girls, people from lower socio-economic backgrounds and Black communities

In October 2023, GSK and Zhifei announce exclusive strategic vaccine partnership in China. Partnership will significantly extend availability of Shingrix in China with co-promotion to healthcare professionals and over 30,000 points of vaccination

Types Covered:

  • Germ Cell Tumors
  • Epithelial Tumors
  • Primary Peritoneal Cancer
  • Stromal Tumors

Therapeutic Treatments Covered:

  • Radiation Therapy
  • Chemotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Surgery
  • Other Therapeutic Treatments

Diagnostic Tests Covered:

  • Ultrasound
  • Computed Tomography (C.T.) Scans
  • Barium Enema X-Ray
  • Chest X-Ray
  • Positron Emission Tomography (PET) Scan
  • Magnetic Resonance Imaging (MRI) Scans
  • Other Diagnostic Tests

End Users Covered:

  • Diagnostic Centers
  • Hospitals
  • Online Pharmacies
  • Drug Stores
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Ovarian Cancer Market, By Type

  • 5.1 Introduction
  • 5.2 Germ Cell Tumors
  • 5.3 Epithelial Tumors
  • 5.4 Primary Peritoneal Cancer
  • 5.5 Stromal Tumors

6 Global Ovarian Cancer Market, By Therapeutic Treatment

  • 6.1 Introduction
  • 6.2 Radiation Therapy
  • 6.3 Chemotherapy
  • 6.4 Hormone Therapy
  • 6.5 Targeted Therapy
    • 6.5.1 PARP Inhibitors
    • 6.5.2 Angiogenesis Inhibitors
    • 6.5.3 PD-L1 Inhibitors
    • 6.5.4 Other Targeted Therapies
  • 6.6 Surgery
  • 6.7 Other Therapeutic Treatments

7 Global Ovarian Cancer Market, By Diagnostic Test

  • 7.1 Introduction
  • 7.2 Ultrasound
  • 7.3 Computed Tomography (C.T.) Scans
  • 7.4 Barium Enema X-Ray
  • 7.5 Chest X-Ray
  • 7.6 Positron Emission Tomography (PET) Scan
  • 7.7 Magnetic Resonance Imaging (MRI) Scans
  • 7.8 Other Diagnostic Tests

8 Global Ovarian Cancer Market, By End User

  • 8.1 Introduction
  • 8.2 Diagnostic Centers
  • 8.3 Hospitals
  • 8.4 Online Pharmacies
  • 8.5 Drug Stores
  • 8.6 Other End Users

9 Global Ovarian Cancer Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbvie Inc
  • 11.2 Amgen Inc.
  • 11.3 Amneal Pharmaceuticals LLC
  • 11.4 AstraZeneca
  • 11.5 Boehringer Ingelheim International GmbH
  • 11.6 Bristol Myers Squibb Company
  • 11.7 Clovis Oncology
  • 11.8 Eli Lilly and Company
  • 11.9 F. Hoffmann-La Roche AG
  • 11.10 Genentech Inc.
  • 11.11 GlaxoSmithKline plc
  • 11.12 Johnson & Johnson Services, Inc
  • 11.13 Merck KGaA
  • 11.14 Novogen, Inc.
  • 11.15 Oasmia Pharmaceutical Inc.
  • 11.16 Pfizer, Inc.
  • 11.17 Siemens Healthineers AG
  • 11.18 Tesaro Inc.
  • 11.19 Vivesto AB

List of Tables

  • Table 1 Global Ovarian Cancer Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Ovarian Cancer Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Ovarian Cancer Market Outlook, By Germ Cell Tumors (2021-2030) ($MN)
  • Table 4 Global Ovarian Cancer Market Outlook, By Epithelial Tumors (2021-2030) ($MN)
  • Table 5 Global Ovarian Cancer Market Outlook, By Primary Peritoneal Cancer (2021-2030) ($MN)
  • Table 6 Global Ovarian Cancer Market Outlook, By Stromal Tumors (2021-2030) ($MN)
  • Table 7 Global Ovarian Cancer Market Outlook, By Therapeutic Treatment (2021-2030) ($MN)
  • Table 8 Global Ovarian Cancer Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 9 Global Ovarian Cancer Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 10 Global Ovarian Cancer Market Outlook, By Hormone Therapy (2021-2030) ($MN)
  • Table 11 Global Ovarian Cancer Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 12 Global Ovarian Cancer Market Outlook, By PARP Inhibitors (2021-2030) ($MN)
  • Table 13 Global Ovarian Cancer Market Outlook, By Angiogenesis Inhibitors (2021-2030) ($MN)
  • Table 14 Global Ovarian Cancer Market Outlook, By PD-L1 Inhibitors (2021-2030) ($MN)
  • Table 15 Global Ovarian Cancer Market Outlook, By Other Targeted Therapies (2021-2030) ($MN)
  • Table 16 Global Ovarian Cancer Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 17 Global Ovarian Cancer Market Outlook, By Other Therapeutic Treatments (2021-2030) ($MN)
  • Table 18 Global Ovarian Cancer Market Outlook, By Diagnostic Test (2021-2030) ($MN)
  • Table 19 Global Ovarian Cancer Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 20 Global Ovarian Cancer Market Outlook, By Computed Tomography (C.T.) Scans (2021-2030) ($MN)
  • Table 21 Global Ovarian Cancer Market Outlook, By Barium Enema X-Ray (2021-2030) ($MN)
  • Table 22 Global Ovarian Cancer Market Outlook, By Chest X-Ray (2021-2030) ($MN)
  • Table 23 Global Ovarian Cancer Market Outlook, By Positron Emission Tomography (PET) Scan (2021-2030) ($MN)
  • Table 24 Global Ovarian Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) Scans (2021-2030) ($MN)
  • Table 25 Global Ovarian Cancer Market Outlook, By Other Diagnostic Tests (2021-2030) ($MN)
  • Table 26 Global Ovarian Cancer Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Ovarian Cancer Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 28 Global Ovarian Cancer Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Ovarian Cancer Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 30 Global Ovarian Cancer Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 31 Global Ovarian Cancer Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.